구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h | |
|---|---|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) | Dupixent (dupilumab) | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Novo Nordisk | Sanofi / Regeneron | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 receptor | IL-4Rα | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Dual incretin mechanism vs GLP-1-only agonists |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration | Non-Type 2 inflammation and inadequate trough levels. | GI side effects during titration; individualized dose escalation required. |
Positioning Development positioning | GLP-1 class anchor vs tirzepatide dual agonist | — | — |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | HbA1c, body weight, lipids. |
PK/PD Half-life | 168 days | ~14 days (300 mg q2w) | 5 h |
PK/PD Species | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) | Mouse, EASI-75, peak pruritus NRS reduction | Mouse, HbA1c ↓2.0%+ |
PK/PD Animal (cat.) | Rat | Mouse | Mouse |
PK/PD Experiment | PK | PD | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat | Mouse | Mouse, Rat |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Clinical Selected reported efficacy | Weight 1.01% | — | — |
Clinical Weight % | weight loss is essential but difficult | — | — |
Clinical Result source | ClinicalTrials.gov NCT03480022 | ClinicalTrials.gov NCT02912468 | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03480022 | NCT02912468 | — |
Preclinical Animal (cat.) | Mouse | — | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h | |
|---|---|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) | Dupixent (dupilumab) | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Novo Nordisk | Sanofi / Regeneron | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 receptor | IL-4Rα | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Dual incretin mechanism vs GLP-1-only agonists |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration | Non-Type 2 inflammation and inadequate trough levels. | GI side effects during titration; individualized dose escalation required. |
Positioning Development positioning | GLP-1 class anchor vs tirzepatide dual agonist | — | — |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | HbA1c, body weight, lipids. |
PK/PD Half-life | 168 days | ~14 days (300 mg q2w) | 5 h |
PK/PD Species | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) | Mouse, EASI-75, peak pruritus NRS reduction | Mouse, HbA1c ↓2.0%+ |
PK/PD Animal (cat.) | Rat | Mouse | Mouse |
PK/PD Experiment | PK | PD | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat | Mouse | Mouse, Rat |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Clinical Selected reported efficacy | Weight 1.01% | — | — |
Clinical Weight % | weight loss is essential but difficult | — | — |
Clinical Result source | ClinicalTrials.gov NCT03480022 | ClinicalTrials.gov NCT02912468 | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03480022 | NCT02912468 | — |
Preclinical Animal (cat.) | Mouse | — | Mouse |
추천 비교
추천 비교